The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
SP2086 is a novel inhibitor of Dipeptide base peptidase 4, allows an insulin-independent
approach to improve type 2 diabetes hyperglycemia. In this single-dose and multiple-dose
study the investigators evaluated the safety, tolerability and PK/PD profiles of SP2086 in
Type 2 Diabetes Patients .